Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
25 hedge funds and large institutions have $68.4M invested in Achilles Therapeutics in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 2 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
0% more funds holding
Funds holding: 25 → 25 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
1.59% less ownership
Funds ownership: 68.15% → 66.56% (-1.6%)
32% less capital invested
Capital invested by funds: $101M → $68.4M (-$32.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$683K |
| 2 |
KHCM
Kettle Hill Capital Management
New York
|
+$600K |
| 3 |
Renaissance Technologies
New York
|
+$140K |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
+$58.2K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$23.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Legal & General Group
London,
United Kingdom
|
-$72K |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$25K |
| 3 |
BlackRock
New York
|
-$15.4K |
| 4 |
JP Morgan Chase
New York
|
-$7.51K |
| 5 |
Goldman Sachs
New York
|
-$2.27K |
ACHL Hedge Fund Activity: Q2 2022 in Review
25 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q2 2022, worth a combined $68.4M — down 32% from $101M a quarter earlier.
Fund positioning in ACHL was balanced in Q2 2022: 2 funds opened new positions, 2 closed out, 7 added to existing stakes and 6 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $683K. The largest seller was Legal & General Group, exiting entirely with an estimated $72K sold.
- 25 institutional investors held Achilles Therapeutics (ACHL) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $68.4M of Achilles Therapeutics stock for Q2 2022, down 32% quarter-over-quarter.
- 2 funds opened new Achilles Therapeutics positions in Q2 2022 and 2 closed out, a net change of 0 holders.
- The largest Achilles Therapeutics buyer in Q2 2022 was Point72 Asset Management, an estimated $683K added.
- The largest Achilles Therapeutics seller in Q2 2022 was Legal & General Group, an estimated $72K sold.
Based on aggregated 13F filings for Q2 2022.